Q1 2026 · 13F-HR
B Group, Inc.holdings as filed
Filed 2026-05-15 · accession 0001420506-26-001023
$134.9M
Reported value
20
Positions
2026-03-31
Period end
The Brief · B Group, Inc. · Q1 2026
AI · grounded in 13F
B Group, Inc. established a new position in NRXP with a $6.39M investment. The fund also opened a new position in DRUG valued at $4.93M and increased its stake in PALI by 153.65%. Conversely, the fund trimmed its holdings in APGE by 62.5% and REPL by 48%.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 000899104 | ADMA | ADMA BIOLOGICS INC | $28.9M | 21.4% | 3,207,542 | Common | SOLE |
| 696389402 | PALI | PALISADE BIO INC | $20.0M | 14.8% | 11,414,285 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $10.7M | 7.94% | 33,237 | Common | SOLE |
| 15117K103 | CLLS | CELLECTIS S A | $10.4M | 7.71% | 3,281,501 | Common | SOLE |
| 98887Q104 | ZLAB | ZAI LAB LTD | $8.5M | 6.28% | 450,646 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $8.0M | 5.97% | 1,800,556 | Common | SOLE |
| 629444209 | NRXP | NRX PHARMACEUTICALS INC | $6.4M | 4.74% | 3,000,000 | Common | SOLE |
| 86366E106 | GPCR | STRUCTURE THERAPEUTICS INC | $6.1M | 4.56% | 127,500 | Common | SOLE |
| 462260100 | IOVA | IOVANCE BIOTHERAPEUTICS INC | $5.3M | 3.90% | 1,500,000 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $5.0M | 3.74% | 100,000 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $4.9M | 3.65% | 67,500 | Common | SOLE |
| 045396207 | ASMB | ASSEMBLY BIOSCIENCES INC | $4.9M | 3.61% | 175,706 | Common | SOLE |
| 05153U107 | AURA | AURA BIOSCIENCES INC | $4.0M | 2.96% | 597,576 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $3.7M | 2.73% | 75,000 | Common | SOLE |
| 82657M105 | SGHT | SIGHT SCIENCES INC | $3.7M | 2.71% | 970,000 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $2.8M | 2.10% | 135,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $631,275 | 0.47% | 7,500 | Common | SOLE |
| 344174107 | FHTX | FOGHORN THERAPEUTICS INC | $487,560 | 0.36% | 102,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $251,100 | 0.19% | 7,500 | Common | SOLE |
| 76029N106 | REPL | REPLIMUNE GROUP INC | $198,900 | 0.15% | 26,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.